Behind SAB’s rapid response to COVID-19
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
SAB had already been working with the U.S. Department of Defense to prepare its human polyclonal antibody platform for rapid responses to new infectious diseases when COVID-19 emerged. The company has since applied its DiversitAb platform to generate SAB-185, a cow-derived human polyclonal antibody therapy that is more consistent and easier to scale up than convalescent plasma from recovered COVID-19 patients.
SAB Biotherapeutics Inc. co-founder and CEO Eddie Sullivan told BioCentury it expects initial lots of SAB-185, which targets the SARS-CoV-2 spike protein, to be ready for clinical testing in early summer. ...